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Organs-on-a-chip systems are biomimetic devices containing microfluidic channels and chambers populated by 
engineered tissues/cells that replicate key functional units of living organs. In these systems, each tissue 
chamber has to be connected to other tissues typically through endothelialized microchannels to accurately 
mimic systemic transport of drugs or soluble factors to/from tissues. We aim to establish this capability by i) 
restoring the physiological phenotype of endothelial cells (ECs) by recapitulating the vascular microenvironment, 
and ii) reproducing tissue-specific drug permeability properties within tissues of interest (e.g. blood-brain-
barrier).    
 
To generate an in vivo-like endothelial phenotype, we first developed a microfluidic system recapitulating both 
physiological shear stress and oxygen levels on ECs. The physiological relevance of this model was validated in 
terms of its responses to a broadly studied vasotoxic chemotherapeutic drug, 5-FU, and to a vasoprotective 
agent, Resveratrol. Next, we developed a microfluidic blood-brain-barrier (BBB) model that is capable of 
mimicking in vivo BBB characteristics for a prolonged period. We derived brain microvascular endothelial cells 
from human induced pluripotent stem cells (iPSCs) and co-cultured them with primary astrocytes on the two 
sides of a porous membrane on a pumpless microfluidic platform. This BBB-on-a-chip model exhibited 
significant barrier integrity as evident by continuous tight junction formation and in vivo-like values of trans-
endothelial electrical resistance (TEER). We further validated the capacity of our microfluidic BBB model to be 
used for drug permeability studies using large molecules (FITC-dextrans) and model drugs (caffeine, cimetidine, 
and doxorubicin). Our BBB-on-a-chip model closely mimics physiological BBB barrier functions and can be used 
for human-relevant screening of drug candidates. 
 
We next focused on the skin vasculature since the current engineered human skin constructs (HSCs) are 
typically maintained under static conditions, which do not allow for studying drug transport between the skin and 
circulation. We employed two separate strategies to address this limitation: (i) developing a skin-on-a-chip 
platform that can create physiologically relevant flow rates; and (ii) incorporating three-dimensional perfusable 
microvasculature into HSCs to recapitulate the endothelial barrier function. In the first strategy, we designed and 
developed a skin-on-a-chip platform that has the capability to recirculate the medium at physiological flow rates 
without the need for a pump or external tube connections. We demonstrated that the platform can be used to 
maintain HSCs for three weeks with proliferating keratinocytes and intact skin barrier function. In the second 
strategy, we micropatterned spatially controlled and perfusable vascular networks in HSCs using both primary 
and iPSC-derived ECs. The 3D-printing technology enabled us to control the geometry of the micropatterned 
vascular networks. We further verified that vascularized human skin constructs can form a robust epidermis and 
establish an endothelial barrier function, which allows for the recapitulation of both topical and systemic delivery 
of drugs. These new vascularization methods now allow us to connect our 3D skin constructs with other 
microphysiological tissues of interest, such as heart and liver, towards building more comprehensive drug 
screening platforms. 
